The updated guidelines provide more detail for when to consider PCSK9 inhibitors to lower LDL, a type of cholesterol that can contribute to fatty deposits in the arteries, which can lead to a heart attack or stroke.
Departments, Centers, & Programs:
Cardiovascular Disease Prevention Center
25 New Chardon Street
Boston, MA 02114-4774
- MMSc, Harvard University
- MD, UC San Francisco School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
- Cardiovascular Disease, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Atherosclerotic cardiovascular disease, including heart attack, is the leading cause of death in the United States. A large proportion of cardiovascular risk is heritable through known (e.g. lipids, blood pressure) and undiscovered mechanisms. Dr. Natarajan leverages natural human genetic variation, biomarkers, human physiology, and digital health to: 1) understand the biology of atherosclerosis in humans; 2) identify new therapeutic targets to reduce cardiovascular risk; 3) predict risk for developing a heart attack; and 4) identify individuals who may benefit from tailored preventive strategies.